PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT

Bibliographic Details
Main Authors:	Jie Zhao, Weiwei Tian
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000976688.08769.5a

Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia/lymphoma with extramedullary disease
by: Jie Zhao, et al.
Published: (2024-04-01)

2496
by: Meryl Sufian, et al.
Published: (2017-09-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
by: Fredrik Schjesvold, et al.
Published: (2022-03-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
by: Fredrik H. Schjesvold, et al.
Published: (2020-06-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
by: Z. Yuping, et al.
Published: (2022-06-01)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Wen LI, et al.
Published: (2023-08-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience
by: İbrahim Halil Açar, et al.
Published: (2023-08-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
by: Juan Du, et al.
Published: (2023-08-01)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
by: Yang Liu, et al.
Published: (2023-08-01)

Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
by: Paul G. Richardson, et al.
Published: (2024-02-01)

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
by: Hitomi Nakayama, et al.
Published: (2024-09-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice
by: Vadim V. Ptushkin, et al.
Published: (2024-12-01)

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
by: Katja C. Weisel, et al.
Published: (2016-07-01)

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
by: Katja Weisel, et al.
Published: (2023-08-01)

PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY
by: Bella Ayubova, et al.
Published: (2023-08-01)

PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS
by: Tassia Cristina Decimoni, et al.
Published: (2023-08-01)

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022-10-01)

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
by: Meletios A. Dimopoulos, et al.
Published: (2015-10-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
by: Kevin W. Song, et al.
Published: (2015-02-01)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
by: Agoston Gyula Szabo, et al.
Published: (2023-11-01)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01)

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
by: Barbara D. Friedes, et al.
Published: (2025-01-01)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
by: Ruth Wester, et al.
Published: (2022-02-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
by: Nizar J Bahlis, et al.
Published: (2023-08-01)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
by: Anna Kalff, et al.
Published: (2021-09-01)

Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement
by: Qiqi Zhang, et al.
Published: (2022-12-01)

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study
by: Arthur Bobin, et al.
Published: (2024-11-01)

P378: THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
by: Y. Wang, et al.
Published: (2022-06-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
by: Di Wang, et al.
Published: (2023-11-01)

Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review
by: Yifan Liu, et al.
Published: (2024-01-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT

Similar Items

Similar Items